Mutual of America Capital Management LLC Sells 9,029 Shares of Orthofix Medical Inc. (NASDAQ:OFIX)

Mutual of America Capital Management LLC reduced its position in Orthofix Medical Inc. (NASDAQ:OFIX) by 5.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 152,347 shares of the medical device company’s stock after selling 9,029 shares during the quarter. Mutual of America Capital Management LLC owned 0.41% of Orthofix Medical worth $2,054,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Legal & General Group Plc grew its stake in shares of Orthofix Medical by 1.0% during the second quarter. Legal & General Group Plc now owns 48,336 shares of the medical device company’s stock worth $1,138,000 after acquiring an additional 485 shares during the last quarter. Osaic Holdings Inc. raised its stake in shares of Orthofix Medical by 4.6% during the 2nd quarter. Osaic Holdings Inc. now owns 12,415 shares of the medical device company’s stock worth $224,000 after buying an additional 546 shares during the period. PNC Financial Services Group Inc. raised its stake in Orthofix Medical by 23.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,960 shares of the medical device company’s stock valued at $53,000 after purchasing an additional 570 shares during the last quarter. MetLife Investment Management LLC raised its stake in Orthofix Medical by 5.4% in the 4th quarter. MetLife Investment Management LLC now owns 11,204 shares of the medical device company’s stock valued at $230,000 after purchasing an additional 570 shares during the last quarter. Finally, Invesco Ltd. increased its stake in shares of Orthofix Medical by 0.5% in the 1st quarter. Invesco Ltd. now owns 127,356 shares of the medical device company’s stock worth $4,164,000 after acquiring an additional 632 shares during the last quarter. 89.76% of the stock is currently owned by institutional investors.

Orthofix Medical Trading Up 0.6 %

NASDAQ:OFIX opened at $13.10 on Friday. The firm has a market cap of $490.07 million, a P/E ratio of -3.16 and a beta of 1.04. The company has a current ratio of 2.54, a quick ratio of 1.20 and a debt-to-equity ratio of 0.19. The stock’s 50 day simple moving average is $13.75 and its 200-day simple moving average is $12.90. Orthofix Medical Inc. has a 12-month low of $9.57 and a 12-month high of $21.60.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings data on Tuesday, March 5th. The medical device company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.01. Orthofix Medical had a negative return on equity of 10.63% and a negative net margin of 20.28%. The firm had revenue of $200.42 million for the quarter. Equities analysts anticipate that Orthofix Medical Inc. will post -1.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. StockNews.com downgraded Orthofix Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Roth Mkm lifted their target price on Orthofix Medical from $12.00 to $15.00 and gave the company a “neutral” rating in a research report on Thursday, March 7th.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.